AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25456442 — intervention group
Group type: COMPARATOR
Intervention: Monocolumn SCS
Number of subjects: 115
Study 25456442 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolumn SCS
Number of subjects: 115
Study 23822684 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (EG)
Number of subjects: 26
Study 23822684 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RG)
Number of subjects: 26
Study 23822684 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study 20712425 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav-Ladach (MLM)
Number of subjects: 180
Study 20712425 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel-Kerr (PKM)
Number of subjects: 180
Study 19561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 82
Study 19561256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bevacizumab treatment)
Number of subjects: 82
Study 16424245 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide (0.1 mmol/kg)
Number of subjects: 247
Study 16424245 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 247
Study 16249974 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg b.i.d. + amoxicillin 1,000 mg + clarithromycin 500 mg (14 days)
Number of subjects: 90
Study 16249974 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg b.i.d. + amoxicillin 1,000 mg + clarithromycin 500 mg (14 days)
Number of subjects: 90
Study 16249974 — intervention group
Group type: COMPARATOR
Intervention: pantoprazole + amoxicillin + clarithromycin
Number of subjects: 90
Study 16249974 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole + amoxicillin + clarithromycin
Number of subjects: 90
Study 11346934 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy in combination with lumpectomy and axillary dissection
Number of subjects: 0
Study 11346934 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision plus radiation therapy
Number of subjects: 0
Study 11346934 — intervention group
Group type: COMPARATOR
Intervention: Breast-conserving therapy
Number of subjects: 0
Study 11346934 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation
Number of subjects: 0
Study 11346934 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary radiation
Number of subjects: 0
Study 11346934 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 0
Study 9692697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (bolus 20 mg, continuous infusion 4 mg/h)
Number of subjects: 10
Study 9692697 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 10
Study 8160985 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30
Study 8160985 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam anesthesia
Number of subjects: 30
Study 8160985 — intervention group
Group type: COMPARATOR
Intervention: Awake control group
Number of subjects: 30
Study 2820920 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 14
Study 2820920 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 14
Study 2820920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29279181 — intervention group
Group type: EXPERIMENTAL
Intervention: Time lapse incubator (TLI)
Number of subjects: 431
Study 29279181 — intervention group
Group type: COMPARATOR
Intervention: Standard incubator (SI)
Number of subjects: 431
Study 26834213 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4/8 mg
Number of subjects: 145
Study 26834213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 26834213 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (all doses)
Number of subjects: 145
Study 26834213 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg
Number of subjects: 145
Study 26834213 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib < 4 mg
Number of subjects: 145
Study 24315152 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear ablation
Number of subjects: 119
Study 24315152 — intervention group
Group type: COMPARATOR
Intervention: CFAE-guided ablation
Number of subjects: 119
Study 23638770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabiotique(®) (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantarum and Bifidobacterium breve) administered daily for 7 days
Number of subjects: 0
Study 23638770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabiotique(®)
Number of subjects: 0
Study 20607528 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbs (Astragalus membranaceus, Salvia miltiorrhiza, and a decoction of six drugs)
Number of subjects: 60
Study 20607528 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbs
Number of subjects: 60
Study 20607528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no traditional Chinese herbs)
Number of subjects: 60
Study 18329573 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual instrumentation using K-type files
Number of subjects: 80
Study 18329573 — intervention group
Group type: COMPARATOR
Intervention: Rotary instrumentation using Hero 642
Number of subjects: 80
Study 16584945 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion palpation (MP) by team A (experienced chiropractor palpating, inexperienced performing treatment)
Number of subjects: 0
Study 16584945 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion palpation (MP) by team B (inexperienced chiropractor palpating, experienced performing treatment)
Number of subjects: 0
Study 14551633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (rehearsing alternative actions)
Number of subjects: 99
Study 14551633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehearsal of alternatives)
Number of subjects: 99
Study 10952955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid daily for 12 weeks
Number of subjects: 100
Study 10952955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8837559 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 (glycoprotein IIb/IIIa antibody) - bolus and 12-hour infusion
Number of subjects: 197
Study 8837559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 8837559 — intervention group
Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 197
Study 8837559 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 197
Study 1430630 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS medical diagnosis
Number of subjects: 360
Study 1430630 — intervention group
Group type: EXPERIMENTAL
Intervention: History of intravenous drug use (IVDU)
Number of subjects: 360
Study 1430630 — intervention group
Group type: COMPARATOR
Intervention: Non-AIDS medical diagnosis
Number of subjects: 360
Study 1430630 — intervention group
Group type: COMPARATOR
Intervention: Non-IVDU history
Number of subjects: 360
Study 1430630 — intervention group
Group type: COMPARATOR
Intervention: Sexual orientation (heterosexual vs. homosexual)
Number of subjects: 360
Study 3781687 — intervention group
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine therapy (two 500 mg tablets t.i.d. for 40 days)
Number of subjects: 40
Study 3781687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 31727514 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane Complete (artificial tears)
Number of subjects: 46
Study 31727514 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 46
Study 28063099 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge PPV (group A)
Number of subjects: 15
Study 28063099 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge PPV (group B)
Number of subjects: 15
Study 26799373 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (Treatment group)
Number of subjects: 94
Study 26799373 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 26799373 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (Treatment group) during partial crossover
Number of subjects: 94
Study 26799373 — intervention group
Group type: COMPARATOR
Intervention: Control group during partial crossover
Number of subjects: 94
Study 26799373 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment throughout the trial
Number of subjects: 94
Study 25255578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (0.75 g/kg bodyweight)
Number of subjects: 10
Study 25255578 — intervention group
Group type: COMPARATOR
Intervention: Sucralose (sweetness-matched with fructose drink)
Number of subjects: 10
Study 22190601 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating water blanket with forced-air warming blanket
Number of subjects: 238
Study 22190601 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming blanket only
Number of subjects: 238
Study 22190601 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming panels
Number of subjects: 238
Study 22190601 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air devices
Number of subjects: 238
Study 20394248 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% epidural lidocaine plus fentanyl
Number of subjects: 120
Study 20394248 — intervention group
Group type: COMPARATOR
Intervention: 0.08% epidural ropivacaine plus fentanyl
Number of subjects: 120
Study 18812323 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive device (catheter thrombus aspiration)
Number of subjects: 6415
Study 18812323 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive device (mechanical thrombectomy)
Number of subjects: 6415
Study 18812323 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive device (embolic protection)
Number of subjects: 6415
Study 18812323 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive device (all types)
Number of subjects: 6415
Study 18089703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pl/E2
Number of subjects: 43
Study 18089703 — intervention group
Group type: EXPERIMENTAL
Intervention: FUL/E2
Number of subjects: 43
Study 18089703 — intervention group
Group type: EXPERIMENTAL
Intervention: FUL/Pl
Number of subjects: 43
Study 15262828 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose in first-use group
Number of subjects: 40
Study 15262828 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose in chronic therapy group
Number of subjects: 40
Study 15262828 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose in both groups
Number of subjects: 40
Study 11350649 — intervention group
Group type: EXPERIMENTAL
Intervention: Betasom hydrogel (polyvinyl‐pyrrolidone‐iodine liposome hydrogel)
Number of subjects: 36
Study 11350649 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine‐gauze
Number of subjects: 36
Study 9164777 — intervention group
Group type: EXPERIMENTAL
Intervention: Similac (milk)
Number of subjects: 72
Study 9164777 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 72
Study 9164777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat
Number of subjects: 72
Study 9164777 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein
Number of subjects: 72
Study 9164777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ross Special Formula
Number of subjects: 72
Study 9164777 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 72
Study 9164777 — intervention group
Group type: COMPARATOR
Intervention: Lactose
Number of subjects: 72
Study 7967421 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 30 Gy in group 1 (stages I, IIA)
Number of subjects: 204
Study 7967421 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 25 Gy in group 2 (stages IIEA, IIB, IIIA)
Number of subjects: 204
Study 7967421 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 20 Gy in group 3 (stages IIEB, IIIB, IV)
Number of subjects: 204
Study 7967421 — intervention group
Group type: COMPARATOR
Intervention: Comparison with precursor studies HD-82 and HD-85
Number of subjects: 204
Study 3668844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (67 g)
Number of subjects: 0
Study 3668844 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (20 mg)
Number of subjects: 0
Study 3668844 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (40 mg)
Number of subjects: 0
Study 3668844 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0, 22, 45 g) and Diazepam (0, 10, 20 mg)
Number of subjects: 0
Study 31883637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 86
Study 31883637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30761720 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 210
Study 30761720 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100 (IGlar U100)
Number of subjects: 210
Study 27647021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147
Study 26544853 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-B vaccine (3 intramuscular injections)
Number of subjects: 30
Study 26544853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24565243 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl (1 μg.kg(‐1) fentanyl, 1mg.kg(‐1) propofol)
Number of subjects: 80
Study 24565243 — intervention group
Group type: COMPARATOR
Intervention: Propofol-alfentanil (10 μg.kg(‐1) alfentanil, 1mg.kg(‐1) propofol)
Number of subjects: 80
Study 21601286 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
Number of subjects: 4360
Study 19570818 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhancing lesions
Number of subjects: 0
Study 19570818 — intervention group
Group type: EXPERIMENTAL
Intervention: Active T2 lesions
Number of subjects: 0
Study 17127572 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic approach based on individual cognitive impairment patterns (single-blind randomised multiple-baseline experiment)
Number of subjects: 8
Study 17127572 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing therapy (baseline phase)
Number of subjects: 8
Study 15175794 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa) 90 microg/kg
Number of subjects: 40
Study 15175794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11360125 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (60 mg elemental iron/day) + albendazole (200 mg/day for 3 consecutive days, repeated 1 month later)
Number of subjects: 177
Study 11360125 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (200 mg/day for 3 consecutive days, repeated 1 month later)
Number of subjects: 177
Study 11360125 — intervention group
Group type: COMPARATOR
Intervention: Iron + albendazole-placebo
Number of subjects: 177
Study 11360125 — intervention group
Group type: COMPARATOR
Intervention: Albendazole + iron-placebo
Number of subjects: 177
Study 11360125 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 177
Study 8988080 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiari malformation group
Number of subjects: 30
Study 8988080 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiari malformation group with basilar invagination
Number of subjects: 30
Study 8988080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120
Study 8424504 — intervention group
Group type: COMPARATOR
Intervention: 4 mg epidural morphine + 3 mL normal saline IM
Number of subjects: 120
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain relief
Number of subjects: 120
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of nausea or vomiting, pruritus, and bleeding
Number of subjects: 120
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of pruritus
Number of subjects: 120
Study 8424504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradyspnea
Number of subjects: 120
Study 3566307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (10-20 mg/m2 i.v., on days 1-5 or 50-100 mg/m2 i.v., on day 1, every 3 to 4 weeks)
Number of subjects: 69
Study 3566307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 69
Study 29281036 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim 80 mg intravenously every 12 hours for 5-14 days
Number of subjects: 600
Study 29281036 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg intravenously every 12 hours for 5-14 days
Number of subjects: 600
Study 27428533 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-massage at the musculotendinous junction for 3 min daily, five times per week, for 12 weeks
Number of subjects: 37
Study 27428533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study 24515493 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated physician small-group curriculum (19 biweekly discussion groups for 9 months) with 1 hour of paid time every other week.
Number of subjects: 74
Study 24515493 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention).
Number of subjects: 74
Study 24515493 — intervention group
Group type: COMPARATOR
Intervention: Nontrial cohort (350 participants).
Number of subjects: 74
Study 22351480 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg MG
Number of subjects: 20
Study 22351480 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg MG (thrice a day for 1 week)
Number of subjects: 20
Study 20215047 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple tailoring and counselling (MTC)
Number of subjects: 15
Study 20215047 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple tailoring (MT)
Number of subjects: 15
Study 20215047 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 15
Study 18374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus sibutramine (10‐20 mg)
Number of subjects: 28
Study 18374423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16227668 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0
Study 16227668 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude version of EBM
Number of subjects: 0
Study 16227668 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial sponsors of clinical trials
Number of subjects: 0
Study 16227668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bureaucrats employing EBM practices
Number of subjects: 0
Study 11777716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine ophthalmic solution 0.5%
Number of subjects: 60
Study 11777716 — intervention group
Group type: COMPARATOR
Intervention: Loteprednol etabonate ophthalmic suspension 0.5%
Number of subjects: 60
Study 9651632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine 1
Number of subjects: 0
Study 9651632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine 2
Number of subjects: 0
Study 8016555 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 mM CHX mouthrinses used twice daily
Number of subjects: 9
Study 8016555 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.9 mM NaF rinses used daily
Number of subjects: 9
Study 8016555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CHX and NaF rinses
Number of subjects: 9
Study 8016555 — intervention group
Group type: COMPARATOR
Intervention: F- rinses alone
Number of subjects: 9
Study 2573964 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (Minipress)
Number of subjects: 344
Study 30253197 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vortioxetine
Number of subjects: 32
Study 30253197 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vortioxetine
Number of subjects: 32
Study 30253197 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg escitalopram
Number of subjects: 32
Study 30253197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27344218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygen saturation target range (85%-89%)
Number of subjects: 810
Study 27344218 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygen saturation target range (91%-95%)
Number of subjects: 810
Study 24724089 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill interval training (4 × 4 minutes at 90‐95% of maximal heart rate, 3 days a week for 8 weeks)
Number of subjects: 24
Study 24724089 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation control group
Number of subjects: 24
Study 23199977 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled procaterol before exercise
Number of subjects: 21
Study 23199977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhaled procaterol)
Number of subjects: 21
Study 20391086 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training (7-week, four sessions a week)
Number of subjects: 27
Study 20391086 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued daily life)
Number of subjects: 27
Study 18795931 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Open Application Test (ROAT) with MDBGN
Number of subjects: 18
Study 18795931 — intervention group
Group type: COMPARATOR
Intervention: Patch Test with MDBGN
Number of subjects: 18